Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. suppl_1, 22-34, May 2007; doi:10.1634/theoncologist.12-S1-22
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, J. L.
Right arrow Articles by Morrow, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, J. L.
Right arrow Articles by Morrow, G. R.

Mechanisms of Cancer-Related Fatigue

Julie L. Ryana,b, Jennifer K. Carrollb,c, Elizabeth P. Ryanb,d, Karen M. Mustianb, Kevin Fiscellac,e, Gary R. Morrowb,f

aDepartment of Dermatology, bDepartment of Radiation Oncology, cDepartment of Family Medicine, dDepartment of Environmental Medicine, eDepartment of Community and Preventive Medicine, and fDepartment of Psychiatry, University of Rochester School of Medicine and Dentistry, James P. Wilmot Cancer Center, Rochester, New York, USA

Key Words. Cancer • Fatigue • Pathophysiology • Etiology

Correspondence: Julie L. Ryan, Ph.D., University of Rochester James P. Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, New York 14642, USA. Telephone: 585-275-2282; Fax: 585-461-5601; e-mail: Julie_Ryan{at}urmc.rochester.edu

Cancer-related fatigue (CRF) is one of the most prevalent symptoms patients with cancer experience, both during and after treatment. CRF is pervasive and affects patients' quality of life considerably. It is important, therefore, to understand the underlying pathophysiology of CRF in order to develop useful strategies for prevention and treatment. At present, the etiology of CRF is poorly understood and the relative contributions of the neoplastic disease, various forms of cancer therapy, and comorbid conditions (e.g., anemia, cachexia, sleep disorders, depression) remain unclear. In any individual, the etiology of CRF probably involves the dysregulation of several physiological and biochemical systems. Mechanisms proposed as underlying CRF include 5-HT neurotransmitter dysregulation, vagal afferent activation, alterations in muscle and ATP metabolism, hypothalamic–pituitary–adrenal axis dysfunction, circadian rhythm disruption, and cytokine dysregulation. Currently, these hypotheses are largely based on evidence from other conditions in which fatigue is a characteristic, in particular chronic fatigue syndrome and exercise-induced fatigue. The mechanisms that lead to fatigue in these conditions provide a theoretical basis for future research into the complex etiology of this distressing and debilitating symptom. An understanding of relevant mechanisms may offer potential routes for its prevention and treatment in patients with cancer.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
Journal of the American Dental AssociationHome page
J. L. Burris, D. R. Evans, and C. R. Carlson
Psychological correlates of medical comorbidities in patients with temporomandibular disorders
J Am Dent Assoc, January 1, 2010; 141(1): 22 - 31.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
L. F. Brown and K. Kroenke
Cancer-Related Fatigue and Its Associations With Depression and Anxiety: A Systematic Review
Psychosomatics, September 1, 2009; 50(5): 440 - 447.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
D. Scrijvers, F. Roila, and On behalf of the ESMO Guidelines Working Group
Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use
Ann. Onc., May 1, 2009; 20(suppl_4): iv159 - iv161.
[Full Text] [PDF]


Home page
Palliat MedHome page
C Lundh Hagelin, Y Wengstrom, E Ahsberg, and C. Furst
Fatigue dimensions in patients with advanced cancer in relation to time of survival and quality of life
Palliative Medicine, March 1, 2009; 23(2): 171 - 178.
[Abstract] [PDF]


Home page
JNCI J Natl Cancer InstHome page
O. Minton, A. Richardson, M. Sharpe, M. Hotopf, and P. Stone
A Systematic Review and Meta-Analysis of the Pharmacological Treatment of Cancer-Related Fatigue
J Natl Cancer Inst, August 20, 2008; 100(16): 1155 - 1166.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
G. R. Morrow
Cancer-Related Fatigue: Causes, Consequences, and Management
Oncologist, May 1, 2007; 12(suppl_1): 1 - 3.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. K. Carroll, S. Kohli, K. M. Mustian, J. A. Roscoe, and G. R. Morrow
Pharmacologic Treatment of Cancer-Related Fatigue
Oncologist, May 1, 2007; 12(suppl_1): 43 - 51.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. M. Mustian, G. R. Morrow, J. K. Carroll, C. D. Figueroa-Moseley, P. Jean-Pierre, and G. C. Williams
Integrative Nonpharmacologic Behavioral Interventions for the Management of Cancer-Related Fatigue
Oncologist, May 1, 2007; 12(suppl_1): 52 - 67.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement